ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer.

As previously reported 15 , 19 , acelERA BC did not reach statistical significance for the primary endpoint of investigator-assessed progression-free survival (INV-PFS), but giredestrant exhibited a numerical improvement over PCET as noted by ~20% relative reduction in risk of progression or death and favorable results for secondary efficacy endpoints.

also in 111,027 other papers